Premium
Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment
Author(s) -
Shilbayeh Sireen A.R.,
Sy Sherwin K.B.,
Melhem Murad,
Zmeili Rawan,
Derendorf Hartmut
Publication year - 2015
Publication title -
clinical pharmacology in drug development
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.711
H-Index - 22
eISSN - 2160-7648
pISSN - 2160-763X
DOI - 10.1002/cpdd.172
Subject(s) - quetiapine , pharmacokinetics , medicine , cyp3a5 , pharmacology , single nucleotide polymorphism , dosing , pharmacogenetics , quetiapine fumarate , population , crossover study , genotype , atypical antipsychotic , biology , antipsychotic , genetics , schizophrenia (object oriented programming) , psychiatry , placebo , alternative medicine , environmental health , pathology , gene
The aim of this study was to evaluate whether genetic polymorphisms in CYP3A5 and ABCB1 are responsible for the interindividual variability observed in quetiapine pharmacokinetics. Pharmacokinetic data from a randomized crossover study evaluating 2 quetiapine 25 mg immediate‐release tablets after single oral dose were used to develop a population pharmacokinetic model. The single nucleotide polymorphisms (SNPs) evaluated for the genotype effects of quetiapine pharmacokinetics were CYP3A5 A6986G and ABCB1 C3435T, along with other demographic variables and formulations. A one‐compartment distribution model with linear elimination plus four transit compartments for the delayed absorption adequately described quetiapine disposition. CYP3A5 *1/*1 individuals (n = 3) had 29% increased clearance compared to *1/*3 and *3/*3 individuals. The impact of an increased clearance was evaluated by simulations. By computing the probability of target attainment (PTA) of steady‐state therapeutic goal at 1‐hour and 12‐hour time points after 50–400 mg twice‐daily regimens, the results indicated that CYP3A5 genotype has minimal impact on the PTA of the 1‐hour concentrations but a significant impact on the 12‐hour concentrations. The interpretation based on the simulations does not call for a genotype‐based dosing scheme and is consistent with consensus guidelines for quetiapine that therapeutic drug monitoring is considered useful. Clinical Pharmacology in Drug Development